Fundraising FoxGilead Sciences — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesWestlake Village BioPartnersKleiner PerkinsNorthpond VenturesOxford Finance LLC+2 more
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies that direct T cells to address autoimmune and inflammatory diseases.
BiotechHealthtech
Co-investorsFuture Planet CapitalGV (Google Ventures)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.